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Abstract Among non-pharmacological treatments, the keto-
genic diet (KD) has the strongest demonstrated evidence of clin-
ical success in drug resistant epilepsy. In an attempt to model the
anticonvulsant effects of the KD pre-clinically, the present study
assessed the effects of the KD against electroshock-induced con-
vulsions in mice. After confirming that exposure to the KD for
2 weeks resulted in stable ketosis and hypoglycemia, mice were
exposed to electroshocks of various intensities to establish gen-
eral seizure susceptibility. When compared to mice fed the stan-
dard rodent chow diet (SRCD), we found that mice fed the KD
were more sensitive to electroconvulsions as reflected by a sig-
nificant decrease in seizure threshold (3.86 mA in mice on the
KD vs 7.29 mA in mice on the SRCD; P<0.05) in the maximal
electroshock seizure threshold (MEST) test. To examine if this
increased seizure sensitivity to electroconvulsions produced by
the KDwould affect anticonvulsant effects of antiepileptic drugs
(AEDs), anticonvulsant potencies of carbamazepine (CBZ),
phenobarbital (PB), phenytoin (PHT), and valproate (VPA)
against maximal electroshock (MES)-induced convulsions were
compared in mice fed the KD and SRCD. We found that poten-
cies of all AEDs studied were decreased in mice fed the KD in
comparison to those on the SRCD, with decreases in the anti-
convulsant potencies ranging from 1.4 fold (PB) to 1.7 fold
(PHT). Finally, the lack of differences in brain exposures of the
AEDs studied in mice fed the KD and SRCD ruled out a phar-
macokinetic nature of the observed findings. Taken together,
exposure to the KD in the present study had an overall pro-
convulsant effect. Since electroconvulsions require large meta-
bolic reserves to support their rapid spread throughout the brain
and consequent generalized tonic-clonic convulsions, this effect
may be explained by a high energy state produced by the KD in
regards to increased energy storage and utilization.












Drug resistant epilepsy continues to be a significant unmet med-





1 Department of Pathophysiology, Medical University, Jaczewskiego
8, 20-090 Lublin, Poland
2 Department of Physiopathology, Institute of Agricultural Medicine,
Jaczewskiego 2, 20-950 Lublin, Poland
3 Chair of Ophthalmology, Medical University, Chmielna 1,
20-079 Lublin, Poland
4 Department of Animal Physiology, Institute of Biology and
Biochemisry, Faculty of Biology and Biotechnology, Maria
Curie-Skłodowska University, Akademicka 19,
20-033 Lublin, Poland
5 Department of Pharmacology and Physiology, Drexel University
College of Medicine, Philadelphia, PA, USA
Metab Brain Dis (2017) 32:351–358
DOI 10.1007/s11011-016-9900-4
antiepileptic drugs (AEDs) (Loscher et al. 2013). In addition to a
continuous effort to improve current AEDs and discover new
small molecules (Bialer et al. 2015), non-pharmacological treat-
ment approaches are increasingly being considered for the treat-
ment of drug refractory epilepsy (Engel 2014; Sharma et al.
2015). Among those, the dietary approach by substituting the
regular diet with the ketogenic diets (KDs) has the strongest
evidence so far of clinical success in drug resistant epilepsy (Li
et al. 2013; Reid et al. 2014). This has fueled interest in under-
standing mechanisms responsible for KD’s anticonvulsant and
perhaps disease-modifying (i.e., antiepileptogenic) properties
(Allen et al. 2014; Danial et al. 2013; Gasior et al. 2006;
Hartman et al. 2007; Masino and Rho 2012). One reductional
way of studying the KD pre-clinically is by evaluating its anti-
convulsant profile across many animal models to look for a
unique phenotypic signature that would differentiate the KD
from clinically approved AEDs.
Animal models of seizures and epilepsy syndromes have
been pivotal in pre-clinical testing of treatments of epilepsy
since the Merritt and Putnam’s demonstration in 1937 of the
anticonvulsant efficacy of phenytoin in a cat model of seizures
induced by an electric shock; since then no AED has been
approved without pre-clinical evidence of its anti-seizure effi-
cacy (Smith et al. 2007; Gasior andWiegand 2012; Bialer et al.
2015). Although there are many seizure tests and epilepsy
models available, the initial assessment of anticonvulsant ef-
fects of a treatment often begins with tests that use an acute
electrical stimulation (e.g. maximal electroshock, MES, test or
closely related the maximal electroshock seizure threshold,
MEST, test) or a chemical agent (e.g. pentylenetetrazol, PTZ)
to induce seizures in mice or rats (Giardina and Gasior 2009;
Smith et al. 2007). Not surprisingly, the MES and MEST tests
had also been used in early (Appleton and De Vivo 1973;
Appleton and DeVivo 1974; Davenport and Davenport 1948;
Millichap et al. 1964; Nakazawa et al. 1983; Otani et al. 1984;
Uhlemann and Neims 1972) and more recent (Bough and
Eagles 2001; Bough et al. 2000; Likhodii et al. 2000;
Thavendiranathan et al. 2000, 2003) studies on the anticonvul-
sant properties of the KDs. Unfortunately, those studies re-
vealed mixed results (i.e. ranging from no effect to anticonvul-
sant or proconvulsant) on the effects of the KDs on seizures in
the MES or MEST seizure tests, which is the case when tested
and compared across other experimental settings (Hartman
et al. 2007; Samala et al. 2008; Masino and Rho 2012).
The aim of the present study was to assess the effects of the
classic KDmost commonly used in clinics (i.e. based on long-
chain fatty acids) against the electroshock-induced convul-
sions in mice. Given the contradictory data on the effects of
the KD on electroshock-induced convulsions from the litera-
ture, no a priori hypothesis was set to be verified. Specifically,
effects of the KD were first assessed in the MEST seizure test
that allowed detection of both pro- and anticonvulsant prop-
erties of a tested treatment modality (Giardina and Gasior
2009). Once pro-convulsant effects of the KD in the MEST
seizure test were established, we sought to establish how it
would affect the anticonvulsant effects of several AEDs in
the MES seizure test. Here, we report for the first time that
the KDweakens the acute anticonvulsant effects of carbamaz-
epine, phenobarbital, phenytoin, and valproic acid in the MES
seizure test without altering their brain exposures in mice.
This paradoxical pharmacodynamic effect of the KD is
discussed in the context of using the MES seizure test for
evaluating anticonvulsant effects of the KD.
Materials and methods
Animals
Male Swiss mice weighing 20–25 g were kept in an
environmentally-controlled vivarium (temperature and rela-
tive humidity, 21±1 °C and 55±3 %, respectively) operating
under a natural light-dark cycle. The animals were housed in
colony cages with free access to food (chow pellets) and tap
water. Only experimentally naive mice were used and exper-
imental groups consisted of at least 8 mice per group. All tests
were performed between 9.00 a.m. and 2.00 p.m. Procedures
involving animals and their care were conducted in accor-
dance with the European Communities Council Directive of
September 22, 2010 (2010/63/EU) and Polish legislation on
animal use in biomedical experiments. The experimental pro-
tocols and procedures listed below were approved by the First
Local Ethics Committee in Lublin and conformed to the
Guide for the Care and Use of Laboratory Animals (www.
nap.edu/readingroom/books/labrats).
Ketogenic diet (KD)
All mice were acclimated to the facility on the regular rodent
chow diet for at least 7 days. Then, all mice were fasted over-
night before being randomly assigned to groups fed either a
KD or continued on the standard rodent chow diet (SRCD) for
the next 2 weeks. The KD used in the present study (Bio-Serv
F3666; 8.6:1 ratio of fat to proteins + carbohydrates) has been
described elsewhere (Bough and Eagles 1999; Bough et al.
2000; Hartman et al. 2008).
Weights of the animals maintained on each diet were mon-
itored throughout the study. In addition, KD-induced ketosis
and glucose levels were monitored. Those measures were per-
formed in mice that were not treated with any drugs nor
underwent any seizure testing. Trunk blood glucose and β-
hydroxybutyrate levels were measured with a Precision Xtra
Advanced Diabetes Management System with Precision Xtra
test strips for measuring blood glucose andβ-hydroxybutyrate
levels (Abbott Diabetes Care Inc., Alameda, CA) as described
by (Hartman et al. 2008; Schwechter et al. 2003). Monitors
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were calibrated at the start of each experiment. Before
collecting blood samples, animals were euthanized in a CO2-
infused plastic chamber. Plasma concentrations of glucose and
β-hydroxybutyrate were expressed in mg/ml and mmol/ml,
respectively.
Drugs
The following AEDs were used: carbamazepine (CBZ; a
gift from Polfa, Starogard Gdanski, Poland), phenobar-
bital (PB; Polfa, Krakow, Poland), phenytoin (PHT;
Polfa, Warszawa, Poland), and valproic acid (VPA; as
magnesium salt; kindly donated by ICN Polfa, Rzeszow,
Poland). CBZ, PB, and PHT were suspended in a 1 %
aqueous solution of Tween 80 (Sigma, St. Louis, MO,
USA) in sterile saline; VPA was dissolved in sterile
saline. Doses of AEDs were expressed as mg/kg body
weight. The AEDs were administered as follows: PHT
at 120 min, PB at 60 min, CBZ and VPA - 30 min
before seizure testing and sampling for pharmacokinetic
studies. The selected pretreatment times for the AEDs
correspond to their peak anticonvulsant activity based
on the available literature and previous experiments.
Electroconvulsions
Electroconvulsions were induced by applying an alternating
current (50 Hz; maximum output voltage 500 V) via ear-clip
electrodes from a rodent shocker generator (type 221; Hugo
Sachs Elektronik, Freiburg, Germany). The stimulus duration
was 0.2 s. Tonic hindlimb extension (i.e., rigid extension of
the hindlimbs that exceeds a 90° angle with the body) was
taken as the endpoint. This apparatus was used to induce sei-
zures in two methodologically different experimental ap-
proaches: maximal electroshock seizure threshold (MEST)
test and maximal electroshock seizure (MES) test (Giardina
and Gasior 2009; Zarnowska et al. 2009).
MEST test
Effects of the KD on the threshold for electroconvulsions were
first assessed in the MEST test. Specifically, separate groups
of mice (n≥8 mice per group) were exposed to currents of
varying intensities until data were collected with at least three
current intensities at which close to 0, 50, and 100 % of ani-
mals exhibited the endpoint. After establishing the current
intensity-effect curve (i.e., current intensity in mAvs. percent-
age of mice convulsing) in mice maintained on the KD or
regular diet, the electroconvulsive threshold was calculated
according to a log-probit method by (Litchfield and
Wilcoxon 1949). The electroconvulsive threshold was
expressed as the median current strength value (CS50) in mA
predicted to produce tonic hindlimb extension in 50 % of the
animals tested (Giardina and Gasior 2009).
MES test
In the MES test, mice were challenged with a current of the
fixed intensity (25 mA) that was 4-5-fold higher than the CS50
value in vehicle-treated control mice (Löscher et al. 1991).
These parameters of stimulation (so called maximal electro-
shock) typically result in all mice to respond with tonus im-
mediately after stimulation. The AEDs administered in mice
fed either the control diet or KD were tested for their ability to
increase the number of animals not responding with tonus
(i.e., protected from tonus) after stimulation. Again, at least
three groups of mice, each consisting of at least 8 animals and
treated with a different dose of the AED alone, were chal-
lenged to collect data where close to 0, 50, and 100 % of
animals were protected from tonic seizures. After constructing
a dose-effect curve (i.e., dose in mg/kg vs. percentage of mice
protected), the protective median effective dose (ED50) value
of the drug tested was calculated according to a log-probit
method (Litchfield and Wilcoxon 1949). Each ED50 value
represented a dose of the test drug (in mg/kg) predicted to
protect 50 % of mice tested against MES-induced extension
of the hindlimbs. In this experimental protocol, an increase in
the anticonvulsant potency of the AED tested would be
reflected by a lower ED50 value of that AED (i.e., its lower
dose necessary to protect 50 % of mice challenged).
Conversely, a decrease in the anticonvulsant potency of the
AED tested would be reflected by a higher ED50 value of that
AED (i.e., its higher dose necessary to protect 50 % of mice
challenged).
Measurement of total brain AED concentrations
Total brain concentrations of the selected AEDs were mea-
sured at doses corresponding to their ED50 or the highest dose
tested in the MES test (n=8 mice per group). Specifically,
mice pretreated with a given AED from groups of mice ex-
posed to the SRCD or KD were decapitated and the whole
brain was collected, weighed, and homogenized using Abbott
buffer (1:2 weight/volume) in an Ultra-Turrax T8 homogeniz-
er (IKA-Werke, Staufen, Germany). The homogenates were
then centrifuged at 10,000g for 10 min and the supernatant
samples of 100 μl were collected and analyzed for AED con-
tent. Total brain concentrations of the classical AEDs (CBZ,
PB, PHT, and VPA) were measured by a fluorescence polar-
ization immunoassay (FPIA) using an analyzer (Abbott TDx)
and manufacturer-supplied reagent kits (Abbott Laboratories,
North Chicago, IL, USA). At least 8 animals were used per
each treatment group and brain concentrations of AEDs were
expressed as group means ±S.D. (n=8) in μg/ml of brain
supe rna t an t . P l a sma l eve l s o f g lucose and β -
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hydroxybutyrate were expressed as group means (± SEM).
The CS50 values in the MEST test and the protective ED50
values of AEDs in the MES test were calculated using the log-
probit method by (Litchfield and Wilcoxon 1949), followed
by the method transforming 95 % confidence limits to stan-
dard error of the mean (Luszczki et al. 2006). Statistical anal-
ysis of data from the MEST and MES tests was performed
with one-way ANOVA followed by the Tukey-Kramer test for
multiple comparisons. Total brain concentrations of AEDs
were statistically analyzed using the unpaired Student’s t-test
or one-way ANOVA followed by the post-hoc Bonferroni’s
test for multiple comparisons. Statistical tests were performed
using GraphPad Prism version 4.0 (GraphPad Software, San
Diego, CA, USA). Differences were considered statistically
significant at P<0.05.
Results
Effect of the KD on the overall behavior and biochemical
parameters
Exposure to the KD for 2 weeks did not have any appar-
ent deleterious effect on mice behavior except for some
(approximately 25–30 %) weight loss that was compara-
ble to the weight loss reported in Hartman et al. 2008.
Development of ketosis and hypoglycemia (as measured
by plasma levels of β-hydroxybutyrate and glucose, re-
spectively) in mice fed the KD for 2 weeks were con-
firmed (β-hydroxybutyrate: 2.3 ± 0.3 mM, N = 23; glu-
cose: 68.7 ± 5.4 mg/ml; N= 16).
Effect of the KD on the threshold for electroconvulsions
in the MEST test
Mice maintained on the KD for 2 weeks were more sensitive
to electroconvulsions as reflected by a significant decrease in
seizure threshold in the MEST test (CS50 in mice fed the KD
versus regular diet: 3.86 mA (95 % confidence limits: 3.24 –
4.60; N=24) versus 7.29 mA (95 % confidence limits: 5.25 –
10.14; N=24); P<0.05 (Litchfield and Wilcoxon 1949)).
Effect of the KD on the anticonvulsant action of AEDs
in the MES test
The anticonvulsant dose-effect function and resulting an-
ticonvulsant ED50 values for each AEDs tested in the













































Fig. 1 Dose-effect function of
CBZ, PB, PHT, and VPA in mice
maintained on either the regular
diet (□) or ketogenic diet (■)
against MES-induced seizures in
mice. Each data point represents
percent of mice protected (N= at
least 8 mice/data point) at a given
dose (doses in mg/kg on
abscissa). Sigmoidal curves are
the result of a least squares fit of
dose-response function for each
AED under each diet regimen.
Points of intersections with the
dashed line at 50 % correspond to
approximate ED50 values of
AEDs; note however that the log-
probit method was used for
calculating ED50 presented in
Table 1 (Litchfield and Wilcoxon
1949); see Table 1 for the
calculated ED50 values for each
AEDs and other details
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The anticonvulsant effects of all AEDs studied were di-
minished in mice fed the KD in comparison to those
maintained on the regular diet. This effect was reflected
by right-ward shifts of the anticonvulsant dose-effect
functions for CBZ, PB, PHT, and VPA in mice fed the
KD in comparison to mice fed the regular diet (Fig. 1);
these resulted in significant decreases in the anticonvul-
sant potencies as measured by ED50 values (Table 1).
Decreases in the anticonvulsant potencies ranged from
1.4 fold (PB) to 1.7 fold (PHT). In the case of VPA, its
anticonvulsant ED50 value in mice fed the KD could not
be established due to dose-limiting toxicity of VPA at
doses higher than 400 mg/kg. Of note, only 25 % of mice
were protected at the dose 400 mg/kg of VPA when fed
the KD, whereas 50 % of mice fed the regular diet were
protected by an estimated dose of VPA 265.9 mg/kg; this
would approximate at least a 1.5-fold shift (i.e., increase)
in VPA’s ED50 value in mice fed the KD in comparison to
those fed the regular diet.
Effects of the KD on brain levels of AEDs
Exposure to the KD for 2 weeks had no effect on the brain
levels of the four AEDs studied (Table 2).
Discussion
In the present study, mice fed the KD for 2 weeks developed
ketosis and hypoglycemia comparable to earlier reports in
which KD’s anticonvulsant effects were demonstrated
(Hartman et al. 2008). Mice fed the KD for 2 weeks were
more susceptible to seizures induced in the MESTseizure test.
Also, anticonvulsant potencies of CBZ, PB, PHT, and VPA
were decreased in the MES seizure test in mice fed the KD.
Effects of the KD on potencies of AEDs studied were not due
to pharmacokinetic interactions since the KD did not change
AEDs’ bioavailability in the brain at the times of their testing
in the MES seizure test. That the KD similarly affected all
AEDs studied with both overlapping and distinct mechanisms
of action (Bialer et al. 2015) suggests that the observed en-
hanced seizure propensity to electroconvulsions induced by
the KD was not due any particular mechanism affected; in-
stead it was more likely representing a non-specific change in
the brain. Taken together, exposure to the KD in the present
study had an overall pro-convulsant effect when tested in mice
when seizures were acutely induced by an electric shock.
Clinical evidence supporting efficacy of the KD in refrac-
tory epilepsy is undeniable (Li et al. 2013; Giordano et al.
2014; Reid et al. 2014). However, establishing efficacy of
the KD under experimental conditions in animals has repeat-
edly proven to be a challenge (Hartman et al. 2007). The
MEST and MES seizure tests were used before in mice and
rats exposed to different KDs and the results of those studies
provided only an inconsistent pattern of responses to this con-
vulsive stimulus with nearly as many reports showing no ef-
ficacy of the KD against electroconvulsions as there are re-
ports showing its anticonvulsant or pro-convulsant effects (see
Introduction). Reconciling reasons for those discrepant results
would be difficult now due to different experimental procures
used in those reports (e.g. different species or strains within
the same species, age of animals, KD compositions, durations
Table 1 Effect of the ketogenic diet (KD) on the protective activity of
carbamazepine (CBZ), phenytoin (PHT), phenobarbital (PB) and
valproate (VPA) against maximal electroshock-induced seizures in mice
Diet AED PT (min) AED ED50 (mg/kg) Potency ratio
SRCD CBZ 30 11.4 (9.6–13.6) 1.56 (1.29–1.88)
KD CBZ 30 17.7 (16.5–19.1)*
SRCD PB 60 26.9 (22.7–31.9) 1.39 (1.13–1.70)
KD PB 37.4 (33.5–41.8)*
SRCD PHT 120 11.3 (10.0–12.9) 1.71 (1.45–2.01)
KD PHT 120 19.4 (17.4–21.5)*
SRCD VPA 30 265.9 (243.5–290.3) ≥1.5
KD VPA 30 ≥400
Results are presented as median effective doses (ED50 in mg/kg;
with 95 % confidence limits in parentheses) required to protect
50 % of animals tested against maximal electroshock-induced sei-
zures and potency ratios (with 95 % confidence limits) calculated by
dividing AED’s ED50 value in mice fed the KD by AED’s ED50
value in mice fed the SRCD. All calculations and statistical com-
parisons were made by a log-probit method (Litchfield and
Wilcoxon 1949). ED50 of VPA could not be established due to
dose-limiting toxicity. Animals were maintained on ketogenic diet
(KD) for at least 14 days. Each antiepileptic drug (AED) was ad-
ministered i.p. at the pre-selected time before seizure testing (second
column)
CBZ carbamazepine, PB phenobarbital, PHT phenytoin, VPA valproic
acid, KD ketogenic diet
*P< 0.05 vs. mice fed the SRCD
Table 2 Effect of the KD administered for 14 days on total brain AED
concentrations
Diet AED ED50 (mg/kg) Brain concentration (μg/ml) P value
SRCD CBZ (17.7) 4.24 ± 0.81 >0.05
KD CBZ (17.7) 4.27 ± 0.79
SRCD PB (37.4) 15.01 ± 2.05 >0.05
KD PB (37.4) 14.70 ± 1.99
SRCD PHT (19.4) 2.63 ± 0.65 >0.05
KD PHT (19.4) 2.40 ± 0.78
SRCD VPA (400) 120.6 ± 11.0 >0.05
KD VPA (400) 119.7 ± 15.9
Data are presented as means ± S.D. (N= 8) in μg/ml of brain supernatant.
Statistical evaluation of data was performed with unpaired Student’s t-
test. For more details see Table 2
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to KD of exposure, or parameters of electroshock seizure
stimulation).
The core of changes produced by the KDs includes ketosis,
hypoglycemia, and an increased overall metabolic state of
neurons. It is well documented that ketone bodies, and acetone
in particular, have anticonvulsant properties across many sei-
zure tests including those induced by electroconvulsions
(Gasior et al. 2008; Likhodii et al. 2003; Rho et al. 2002).
Thus, ketosis is unlikely to be the cause of increased seizure
sensitivity to electroconvulsions as observed in the present
study. On the contrary, ketosis would rather be more likely
to offer some attenuation of the KD-facilitated spread of sei-
zures induced by an electric shock.
The role of low glucose levels in seizure sensitivity is more
complex (Schwechter et al. 2003). Low glucose levels are
necessary for maintaining seizure suppression in animals and
patients on the KD (Greene et al. 2001; Huttenlocher 1976).
On the other hand, low blood glucose levels as induced by
insulin excess, for example, can result in seizures in humans
(Cryer 1999; Malouf and Brust 1985). Similarly, low glucose
precipitates seizure activity or lowers seizure threshold in an-
imals (Kaul et al. 1980; Kirchner et al. 2006; Reid et al. 2011;
Waltregny et al. 1966). Of note, 2-Deoxy-D-glucose, a glu-
cose analog that accumulates in cells and interferes with car-
bohydrate metabolism by inhibiting glycolytic enzymes, pro-
motes seizures in the MEST seizure test while behaving as an
anticonvulsant in other seizure tests (Gasior et al. 2010; Sutula
et al. 2006). Taken together, these findings point to the role of
low glucose levels in increasing seizure susceptibility, and that
the seizure tests utilizing electroconvulsions may be particu-
larly useful for revealing this effect.
KD diets have been shown to increase energy storage and
its utilization efficiency (Bough 2008; Bough et al. 2006).
Electroshock is a way of applying an electric stimulation to
the brain. Electrical simulation with high current intensities
such as those used in the MEST and MES tests results in
almost instantaneous activation of the brainstem followed by
a rapid spread of neuronal activation to other brain regions and
to the spinal cord to finally manifest as observable convul-
sions (Browning et al. 1981a, b; Eells et al. 2004; Peterson
1998). After the electroshock is delivered, seizure activity in
the brain and consequent convulsions are induced within mil-
liseconds to seconds. This rapid electrophysiological response
is likely to be possible only when neurons and their connec-
tions are physiologically viable, as is the case when healthy,
non-epileptic animals are used in seizure testing (Gasior and
Wiegand 2012). Second, this excessive neuronal activity is
likely to rapidly increase the rate of energy use and thus must
rely on sufficient energy reserves to support itself (Fujikawa
et al. 1989; Meldrum and Chapman 1999; Wasterlain et al.
2010; Yang et al. 2013). Indeed, KDs, due to their effect on
increasing energy storage and utilization efficiency, may inad-
vertently create an environment that facilitates spread of high
energy-demanding electroconvulsions, as seen in the present
study.
In summary, the results of the present study show that mice
fed the KD become more sensitive to electroconvulsions un-
der experimental parameters such as those used in this study.
Since electroconvulsions require large metabolic reserves, this
effect may be explained by a high energy state produced by
the KD in regards to increased energy storage and utilization.
Demonstration of the pro-convulsant effects of the KD against
seizures induced by electroconvulsions does not diminish the
utility ofMES/MEST-based seizure tests in pre-clinical testing
of potential anticonvulsant therapies. On the contrary, one can
argue that these seizure tests may experimentally differentiate
therapies that work through targets classically linked to epi-
lepsy (eg, GABA, NMDA/AMPA, Na+, Ca2+, K+) from those
that affect, for example, neuronal metabolism. Lastly, the re-
sults reported herein have an effect beyond epilepsy in that
they provide a pre-clinical warning signal for the use of the
electroconvulsive therapy in psychiatric patients who are on
the KD seeking its potential therapeutic benefit or as a lifestyle
choice (e.g. for weight control).
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Allen BG, Bhatia SK, Anderson CM, Eichenberger-Gilmore JM,
Sibenaller ZA, Mapuskar KA, Schoenfeld JD, Buatti JM, Spitz
DR, Fath MA (2014) Ketogenic diets as an adjuvant cancer therapy:
History and potential mechanism. Redox Biol 2C:963–970
Appleton DB, De Vivo DC (1973) An experimental animal model for the
effect of ketogenic diet on epilepsy. Proc Aust Assoc Neurol 10:75–
80
Appleton DB, DeVivo DC (1974) An animal model for the ketogenic
diet. Epilepsia 15:211–227
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS
(2015) Progress report on new antiepileptic drugs: A summary of the
Twelfth Eilat Conference (EILAT XII). Epilepsy Res 111:85–141
Bough K (2008) Energy metabolism as part of the anticonvulsant mech-
anism of the ketogenic diet. Epilepsia 49 Suppl 8:91–93
Bough KJ, Eagles DA (1999) A ketogenic diet increases the resistance to
pentylenetetrazole-induced seizures in the rat. Epilepsia 40:138–143
Bough KJ, Eagles DA (2001) Comparison of the anticonvulsant effica-
cies and neurotoxic effects of valproic acid, phenytoin, and the ke-
togenic diet. Epilepsia 42:1345–1353
Bough KJ,Matthews PJ, Eagles DA (2000) A ketogenic diet has different
effects upon seizures induced by maximal electroshock and by
pentylenetetrazole infusion. Epilepsy Res 38:105–114
Bough KJ, Wetherington J, Hassel B, Pare JF, Gawryluk JW, Greene JG,
Shaw R, Smith Y, Geiger JD, Dingledine RJ (2006) Mitochondrial
biogenesis in the anticonvulsant mechanism of the ketogenic diet.
Ann Neurol 60:223–235
356 Metab Brain Dis (2017) 32:351–358
Browning RA, Simonton RL, Turner FJ (1981a) Antagonism of experi-
mentally induced tonic seizures following a lesion in the midbrain
tegmentum. Epilepsia 22:595–601
Browning RA, Turner FJ, Simonton RL, BundmanMC (1981b) Effect of
midbrain and pontine tegmental lesions on the maximal electro-
shock seizure pattern in rats. Epilepsia 22:583–594
Cryer PE (1999) Symptoms of hypoglycemia, thresholds for their occur-
rence, and hypoglycemia unawareness. Endocrinol Metab Clin
North Am 28:495–4vi
Danial NN, Hartman AL, Stafstrom CE, Thio LL (2013) How does the
ketogenic diet work? Four potential mechanisms. J Child Neurol 28:
1027–1033
Davenport VD, Davenport HW (1948) The relation between starvation, met-
abolic acidosis and convulsive seizures in rats. J Nutr 36:139–151
Eells JB, Clough RW, Browning RA, Jobe PC (2004) Comparative
fos immunoreactivity in the brain after forebrain, brainstem, or
combined seizures induced by electroshock, pentylenetetrazol,
focally induced and audiogenic seizures in rats. Neuroscience
123:279–292
Engel J Jr (2014) Approaches to refractory epilepsy. Ann Indian Acad
Neurol 17:S12–S17
Fujikawa DG, Dwyer BE, Lake RR,Wasterlain CG (1989) Local cerebral
glucose utilization during status epilepticus in newborn primates.
Am J Physiol 256:C1160–C1167
Gasior M,Wiegand F (2012) Epilepsy and the integration of translational
medicine. In: Barrett JE, Williams M, Coyle JT (eds) Translational
neuroscience: applications in neurology, psychiatry and
neurodevelopmental disorders. Cambridge University Press, p
228–252
Gasior M, Rogawski MA, Hartman AL (2006) Neuroprotective and
disease-modifying effects of the ketogenic diet. Behav Pharmacol
17:431–439
Gasior M, Hartman AL, Rogawski MA (2008) The anticonvulsant activ-
ity of acetone does not depend upon its metabolites. Epilepsia 49:
936–937
Gasior M, Yankura J, Hartman AL, French A, Rogawski MA (2010)
Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose.
Epilepsia 51:1385–1394
Giardina WJ, Gasior M (2009) Acute seizure tests in epilepsy research:
electroshock- and chemical-induced convulsions in the mouse. Curr
Protoc Pharmacol 45:5.22.1–5.22.37
Giordano C, Marchio M, Timofeeva E, Biagini G (2014) Neuroactive
peptides as putative mediators of antiepileptic ketogenic diets.
Front Neurol 5:1–14
Greene AE, Todorova MT, McGowan R, Seyfried TN (2001) Caloric
restriction inhibits seizure susceptibility in epileptic EL mice by
reducing blood glucose. Epilepsia 42:1371–1378
Hartman AL, Gasior M, Vining EP, Rogawski MA (2007) The neuro-
pharmacology of the ketogenic diet. Pediatr Neurol 36:281–292
Hartman AL, Lyle M, Rogawski MA, Gasior M (2008) Efficacy of the
ketogenic diet in the 6-Hz seizure test. Epilepsia 49:334–339
Huttenlocher PR (1976) Ketonemia and seizures: metabolic and anticon-
vulsant effects of two ketogenic diets in childhood epilepsy. Pediatr
Res 10:536–540
Kaul CL, David J, Grewal RS (1980) The incidence of electroshock and
pentylenetetrazole (Metrazol) induced convulsions in
hypoglycaemic and acute and chronic hyperglycaemic states in
mice. Pharmacol Res Commun 12:791–803
Kirchner A, Veliskova J, Velisek L (2006) Differential effects of low
glucose concentrations on seizures and epileptiform activity
in vivo and in vitro. Eur J Neurosci 23:1512–1522
Li HF, Zou Y, Ding G (2013) Therapeutic success of the ketogenic diet as
a treatment option for epilepsy: a meta-analysis. Iran J Pediatr 23:
613–620
Likhodii SS, Musa K, Mendonca A, Dell C, BurnhamWM, Cunnane SC
(2000) Dietary fat, ketosis, and seizure resistance in rats on the
ketogenic diet. Epilepsia 41:1400–1410
Likhodii SS, Serbanescu I, Cortez MA, Murphy P, Snead OC III,
Burnham WM (2003) Anticonvulsant properties of acetone, a
brain ketone elevated by the ketogenic diet. Ann Neurol 54:
219–226
Litchfield JT,Wilcoxon F (1949) A simplifiedmethod of evaluating dose-
effect experiments. J Pharmacol Exp Ther 96:99–113
Löscher W, Fassbender CP, Nolting B (1991) The role of technical, bio-
logical and pharmacological factors in the laboratory evaluation of
anticonvulsant drugs. II. Maximal electroshock seizure models.
Epilepsy Res 8:79–94
Loscher W, Klitgaard H, Twyman RE, Schmidt D (2013) New avenues
for anti-epileptic drug discovery and development. Nat Rev Drug
Discov 12:757–776
Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ (2006)
Isobolographic analysis of interactions between loreclezole and con-
ventional antiepileptic drugs in the mouse maximal electroshock-
induced seizure model. Naunyn Schmiedebergs Arch Pharmacol
373:169–181
Malouf R, Brust JC (1985) Hypoglycemia: causes, neurological manifes-
tations, and outcome. Ann Neurol 17:421–430
Masino SA, Rho JM (2012) Mechanisms of Ketogenic Diet Action. In:
Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta
AV, (eds) Jasper’s basic mechanisms of the epilepsies [Internet]. 4th
edition. National Center for Biotechnology Information (US),
Bethesda
Meldrum BS, Chapman AG (1999) Metabolic consequences of seizures.
In: Basic neurochemistry: molecular, cellular and medical aspects.
6th edition. Lippincott-Raven, Philadelphia
Millichap JG, Jones JD, Rudis BP (1964) Mechanism of anticon-
vulsant action of ketogenic diet. Studies in animals with
experimetnal seizures and in children with Petit Mal epilepsy.
Am J Dis Child 107:593–604
Nakazawa M, Kodama S, Matsuo T (1983) Effects of ketogenic diet on
electroconvulsive threshold and brain contents of adenosine nucle-
otides. Brain Dev 5:375–380
Otani K, Yamatodani A,Wada H,Mimaki T, Yabuuchi H (1984) Effect of
ketogenic diet on the convulsive threshold and brain amino acid and
monoamine levels in young mice. No To Hattatsu 16:196–204
Peterson SL (1998) Electroshock. In: Peterson SL, Albertson TE (eds)
Neuropharmacology methods in epilepsy research. CRC Press,
Boca Raton, pp 1–26
Reid CA, Kim TH, Berkovic SF, Petrou S (2011) Low blood glucose
precipitates spike-and-wave activity in genetically predisposed ani-
mals. Epilepsia 52:115–120
Reid CA, Mullen S, Kim TH, Petrou S (2014) Epilepsy, energy deficien-
cy and new therapeutic approaches including diet. Pharmacol Ther
144:192–201
Rho JM, Anderson GD, Donevan SD, White HS (2002) Acetoacetate,
acetone, and dibenzylamine (a contaminant in l-(+)-beta-
hydroxybutyrate) exhibit direct anticonvulsant actions in vivo.
Epilepsia 43:358–361
Samala R,Willis S, Borges K (2008) Anticonvulsant profile of a balanced
ketogenic diet in acute mouse seizure models. Epilepsy Res 81:119–
127
Schwechter EM, Veliskova J, Velisek L (2003) Correlation between ex-
tracellular glucose and seizure susceptibility in adult rats. Ann
Neurol 53:91–101
Sharma AK, Rani E, Waheed A, Rajput SK (2015) Pharmacoresistant
epilepsy: a current update on non-conventional pharmacological
and non-pharmacological interventions. J Epilepsy Res 5:1–8
Smith M, Wilcox KS, White HS (2007) Discovery of antiepileptic drugs.
Neurotherapeutics 4:12–17
Metab Brain Dis (2017) 32:351–358 357
Sutula TP, Ockuly JC, Stafstrom CE, Roopra AS (2006) Novel anticon-
vulsant, antiepileptic properties and favorable toxicology profile of
2-deoxy-d-glucose (2DG) in experimental models of epilepsy.
Epilepsia 47(Suppl 4):324
Thavendiranathan P,MendoncaA,Dell C, Likhodii SS,MusaK, IracleousC,
Cunnane SC,BurnhamWM(2000) TheMCTketogenic diet: effects on
animal seizure models. Exp Neurol 161:696–703
Thavendiranathan P, Chow C, Cunnane S, McIntyre BW (2003) The
effect of the ‘classic’ ketogenic diet on animal seizure models.
Brain Res 959:206–213
Uhlemann ER, Neims AH (1972) Anticonvulsant properties of the keto-
genic diet in mice. J Pharmacol Exp Ther 180:231–238
Waltregny A, Mesdjian E, Gastaut H (1966) Hypoglycemia and the
pentetrazole threshold. C R Seances Soc Biol Fil 160:1912–1914
Wasterlain CG, Thompson KW, Suchomelova L, Niquet J (2010) Brain
energy metabolism during experimental neonatal seizures.
Neurochem Res 35:2193–2198
Yang H, Wu J, Guo R, Peng Y, Zheng W, Liu D, Song Z (2013)
Glycolysis in energy metabolism during seizures. Neural Regen
Res 8:1316–1326
Zarnowska I, Luszczki JJ, Zarnowski T, Buszewicz G, Madro R,
Czuczwar SJ, Gasior M (2009) Pharmacodynamic and pharmacoki-
netic interactions between common antiepileptic drugs and acetone,
the chief anticonvulsant ketone body elevated in the ketogenic diet
in mice. Epilepsia 50:1132–1140
358 Metab Brain Dis (2017) 32:351–358
